Literature DB >> 18539969

Melanoma stem cells: the dark seed of melanoma.

Susan E Zabierowski1, Meenhard Herlyn.   

Abstract

Cells with stem-cell markers and features have recently been identified in melanoma tissues and cell lines. Melanoma stem-like cells possess many traits of tumor-initiating or tumor stem cells including self-renewal capacity, high tumorigenicity, and differentiation into various mesenchymal lineages, including melanocytic cells. Four subpopulations of melanoma-initiating cells have been distinguished: CD20(+), CD133(+), label-retaining or slow-cycling cells, and side-population cells with high efflux activities. Whether these are distinct or overlapping populations is currently under investigation. Ongoing studies are dissecting and characterizing the hierarchy of these subpopulations within a malignant lesion. Understanding these and the dynamics of clonal dominance will aid in the development of novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18539969     DOI: 10.1200/JCO.2007.15.5465

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  54 in total

1.  The RP-p53-Mdm2 pathway: a new link to genetic integrity?

Authors:  Rebeca A Frum; Yanping Zhang
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

Review 2.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

Review 3.  Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Authors:  József Tímár; Balázs Gyorffy; Erzsébet Rásó
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

4.  A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Authors:  Alexander Roesch; Mizuho Fukunaga-Kalabis; Elizabeth C Schmidt; Susan E Zabierowski; Patricia A Brafford; Adina Vultur; Devraj Basu; Phyllis Gimotty; Thomas Vogt; Meenhard Herlyn
Journal:  Cell       Date:  2010-05-14       Impact factor: 41.582

Review 5.  Dendritic cell vaccines for melanoma: past, present and future.

Authors:  Robert O Dillman; Gabriel I Nistor; Andrew N Cornforth
Journal:  Melanoma Manag       Date:  2016-11-29

6.  Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma.

Authors:  Caroline I Schnegg; Moon Hee Yang; Subrata K Ghosh; Mei-Yu Hsu
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

7.  Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.

Authors:  Andy J Chien; Erin C Moore; Anke S Lonsdorf; Rima M Kulikauskas; Bonnie Gould Rothberg; Aaron J Berger; Michael B Major; Sam T Hwang; David L Rimm; Randall T Moon
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-14       Impact factor: 11.205

8.  Rapid selection and proliferation of CD133+ cells from cancer cell lines: chemotherapeutic implications.

Authors:  Sarah E Kelly; Altomare Di Benedetto; Adelaide Greco; Candace M Howard; Vincent E Sollars; Donald A Primerano; Jagan V Valluri; Pier Paolo Claudio
Journal:  PLoS One       Date:  2010-04-08       Impact factor: 3.240

9.  Skeletal muscle phenotypically converts and selectively inhibits metastatic cells in mice.

Authors:  Ara Parlakian; Iman Gomaa; Sounkary Solly; Ludovic Arandel; Alka Mahale; Gustav Born; Giovanna Marazzi; David Sassoon
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

Review 10.  Main roads to melanoma.

Authors:  Giuseppe Palmieri; Mariaelena Capone; Maria Libera Ascierto; Giusy Gentilcore; David F Stroncek; Milena Casula; Maria Cristina Sini; Marco Palla; Nicola Mozzillo; Paolo A Ascierto
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.